B. Riley Expects Lower Earnings for Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a research note issued to investors on Tuesday, May 6th. B. Riley analyst K. Patel now expects that the biotechnology company will post earnings of $0.14 per share for the quarter, down from their previous forecast of $0.18. B. Riley currently has a "Neutral" rating and a $24.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals' Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.16 EPS and FY2027 earnings at $1.44 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.49. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The business had revenue of $53.33 million during the quarter, compared to the consensus estimate of $43.87 million. During the same quarter last year, the firm posted ($0.50) EPS.

RIGL has been the subject of several other reports. Cantor Fitzgerald increased their price objective on Rigel Pharmaceuticals from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. StockNews.com downgraded shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 8th. HC Wainwright reiterated a "buy" rating and issued a $57.00 target price on shares of Rigel Pharmaceuticals in a report on Wednesday, March 5th. Finally, Citigroup raised their price target on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $36.40.

Rigel Pharmaceuticals Trading Up 0.3%

Shares of RIGL traded up $0.05 on Friday, reaching $18.34. The company's stock had a trading volume of 144,629 shares, compared to its average volume of 212,963. Rigel Pharmaceuticals has a twelve month low of $7.48 and a twelve month high of $29.82. The stock has a market capitalization of $327.77 million, a PE ratio of 131.01 and a beta of 1.34. The firm has a fifty day moving average of $18.51 and a 200-day moving average of $19.88.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Soleus Capital Management L.P. raised its position in Rigel Pharmaceuticals by 21.0% in the fourth quarter. Soleus Capital Management L.P. now owns 1,130,679 shares of the biotechnology company's stock worth $19,018,000 after acquiring an additional 195,891 shares during the period. Vanguard Group Inc. raised its holdings in shares of Rigel Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 1,028,072 shares of the biotechnology company's stock worth $18,495,000 after purchasing an additional 15,141 shares during the period. Assenagon Asset Management S.A. lifted its stake in Rigel Pharmaceuticals by 27.3% in the first quarter. Assenagon Asset Management S.A. now owns 522,781 shares of the biotechnology company's stock valued at $9,405,000 after purchasing an additional 112,003 shares during the last quarter. Geode Capital Management LLC grew its holdings in Rigel Pharmaceuticals by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 402,051 shares of the biotechnology company's stock valued at $6,764,000 after purchasing an additional 2,388 shares during the period. Finally, Renaissance Technologies LLC increased its position in Rigel Pharmaceuticals by 111.1% in the fourth quarter. Renaissance Technologies LLC now owns 299,709 shares of the biotechnology company's stock worth $5,041,000 after buying an additional 157,763 shares during the last quarter. 66.23% of the stock is owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.